汉瑞药业(荆门)有限公司

6
Years

公司简介

查看全部
汉瑞药业(荆门)有限公司坐落于湖北省荆门市化工循环产业园,占地面积310亩,设计3个GMP多功能车间,4个GMP商业化车间,6个Non-GMP车间。反应釜体积30L~10000L,涵盖高、低温,氢化。可供奥格列龙ORFORGLIPRON中间体产品。
汉瑞药业(荆门)有限公司
主要销售市场
北美洲,亚洲
成立年份
2019
人员规模
150至199
年销售额(USD)
不愿意公开
联系人
Qin Pan
联系电话
13659896961
快速询盘
请输入询盘主题
请输入询盘信息
快速发送询盘

新闻资讯

查看全部
Breakthrough in Green and Economical Synthesis of Key GLP-1 Intermediate
At Hiray Pharma Solutions, our R&D team continues to deepen process innovation around key intermediates of next-generation metabolic drugs. Today, we are pleased to share progress on a more efficient and industrially viable synthesis of (4-Fluoro-3,5-dimethylphenyl)hydrazine hydrochloride, a crucial intermediate of Eli Lilly’s oral GLP-1 candidate Orforglipron.*What We Improved The original patented route relies on a palladium-catalyzed Buchwald coupling — effective, but costly and less suitable for large-scale industrial adoption.Our team developed an improved pathway by replacing Pd catalysts with a cost-effective copper-catalyzed Ullmann reaction, achieving both scalability and economic advantage.* Key Technical Highlights✔ Copper bromide (CuBr2) used as catalyst— Avoids catalyst oxidation poisoning often seen with Cu salts— Delivers 80% overall yield of the target hydrazine intermediate✔ Ligand engineering for catalytic efficiency— A redox-active pyrrolyl hydrazide ligand enables Cu(II)/Cu(III) catalytic cycling— Facilitates smooth oxidative addition and C–N bond formation✔ Significant cost reductionReplacing palladium acetate with inexpensive copper bromide greatly improves competitiveness for commercial-scale production.*Process Optimization Results1. Hydrazine hydrate equivalentsIncreasing hydrazine equivalents elevated compound purity from 86.4% → 94.3%. 2. Catalyst screeningCuBr and CuI demonstrated superior performance, giving >92% purity of the desired product. 3. Solvent selectionDMSO proved optimal and robust for scale-up, outperforming alternative solvents such as isopropyl acetate, t-butanol, and Me-THF. *Why This MattersOrforglipron represents a promising direction in non-peptide oral GLP-1 therapies. By optimizing upstream intermediates with scalable, cost-competitive synthesis routes, Hiray Pharma strengthens its position as a dependable partner for global pharmaceutical development and manufacturing. We will continue investing in innovation that accelerates high-quality, industrially robust API and intermediate supply for partners worldwide.
2025-12-03
查看详情
2006-2026 上海博华国际展览有限公司版权所有(保留一切权利)
沪ICP备05034851号-57